homocamptothecin profile

homocamptothecin: a DNA topoisomerase I antagonists, is a semisynthetic analogue of camptothecin (CPT) with a seven-membered beta-hydroxylactone resulting from the insertion of a mehthylene spacer between the alcohol moiety and the carboxyl function of the naturally occurring six-membered alpha-hydroxylactone of CPT; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	10666346
CHEMBL ID	74190
CHEBI ID	144047
SCHEMBL ID	5860320
MeSH ID	M0307083

Synonym
CHEMBL74190
homocamptothecin
CHEBI:144047
(5r)-5-ethyl-5-hydroxy-1,4,5,13-tetrahydro-3h,15h-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione
e-homocamptothecine
e-homocamptothecin
3h,15h-oxepino(3',4':6,7)indolizino(1,2-b)quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-, (5r)-
unii-5b3lfu8glm
3h,15h-oxepino(3',4':6,7)indolizino(1,2-b)quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-, (r)-
186669-19-2
e-homocamptothecin, (r)-
5b3lfu8glm ,
(20r)-homocamptothecin
SCHEMBL5860320
PAEZRCINULFAGO-OAQYLSRUSA-N
(20r)-20-ethyl-20-hydroxy-17-oxa-3,13-diazapentacyclo[11.9.0.02,11.04,9.015,21]docosa-1(22),2,4,6,8,10,15(21)-heptaene-14,18-dione
Q27261770
(r)-e-homocamptothecin
(r)-5-ethyl-5-hydroxy-1,4,5,13-tetrahydro-3h,15h-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione

Research Excerpts

Overview

Homocamptothecins (hCPTs) are a novel class of topoisomerase I (Top1) inhibitors with enhanced chemical stability compared with the currently used camptothecin (CPT) analogs irinotecan and topotecans.

Excerpt	Reference	Relevance
"Homocamptothecin (hCPT) is an E-ring modified camptothecin (CPT) analogue bearing a methylene spacer between the alcohol and carboxyl functions of the CPT lactone. "	( Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins. Bailly, C; Baroggi, N; Bigg, DC; Camara, J; Cazaux, JB; Coulomb, H; Demarquay, D; Huchet, M; Lanco, C; Lavergne, O; Le Breton, C; Manginot, E; Muller, N; Rolland, A, 2000)	1.97
"Homocamptothecin (hCPT) is a camptothecin (CPT) homologue with the insertion of a methylene (CH₂) spacer between the alcohol moiety and carbonyl group of the classical six-membered α-hydroxylactone ring. "	( Synthesis and biological evaluation of novel homocamptothecins conjugating with dihydropyrimidine derivatives as potent topoisomerase I inhibitors. Cheng, P; Dong, G; Guo, W; Lei, N; Liu, W; Miao, Z; Sheng, C; Wang, S; Yao, J; Zhang, W; Zhang, Y; Zhu, L; Zhuang, C, 2011)	2.07
"Homocamptothecin (hCPT) is a camptothecin (CPT) derivative with a seven-membered β-hydroxylactone E ring, which shows higher lactone stability and improves topoisomerase I (Topo I) inhibition activity. "	( Synthesis and biological evaluation of 7-alkenyl homocamptothecins as potent topoisomerase I inhibitors. Cheng, P; Dong, G; Guo, W; Lei, N; Liu, W; Miao, Z; Sheng, C; Yao, J; Zhang, W; Zhang, X; Zhu, L; Zhuang, C, 2012)	2.08
"Homocamptothecin is a lead compound for inhibiting Top1, and is composed of five conjugated planar rings (A-E)."	( Analysis of human topoisomerase I inhibition and interaction with the cleavage site +1 deoxyguanosine, via in vitro experiments and molecular modeling studies. Burke, TG; Curran, DP; Du, W; Jerina, DM; Kohlhagen, G; Laco, GS; Pommier, Y; Sayer, JM, 2004)	1.04
"Homocamptothecins (hCPTs) are a novel class of topoisomerase I (Top1) inhibitors with enhanced chemical stability compared with the currently used camptothecin (CPT) analogs irinotecan and topotecan. "	( Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan. Bates, SE; Guirouilh-Barbat, J; Liao, Z; Polgar, O; Pommier, Y; Robey, RW; To, KK, 2008)	2
"Homocamptothecin (hCPT) is a semisynthetic analogue of camptothecin (CPT) with a seven-membered beta-hydroxylactone resulting from the insertion of a methylene spacer between the alcohol moiety and the carboxyl function of the naturally occurring six-membered alpha-hydroxylactone of CPT. "	( Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Bailly, C; Bigg, DC; Camara, J; Dassonneville, L; Demarquay, D; Kasprzyk, PG; Kiss, R; Lavergne, O; Lesueur-Ginot, L, 1999)	3.19

Pharmacokinetics

Excerpt	Reference	Relevance
" The drug concentration in plasma was determined and the pharmacokinetic behaviour was compared."	( [In vivo imaging in tumor-bearing animals and pharmacokinetics of PEGylated liposomes modified with RGD cyclopeptide]. Deng, LH; Tang, CY; Tu, LX; Wu, CB; Xu, YH, 2012)	0.38

Bioavailability

Excerpt	Reference	Relevance
" So it supplied the possibility of improving oral bioavailability of HCPT when combining together admoveatur of P-gp inhibitor, CsA."	( [Pharmaceutical evaluation of hydroxycamptothecin nanosuspensions with the action of inhibiting P-gp]. He, ZG; Pu, XH; Qin, YM; Sun, J; Zhang, P; Zhang, X, 2011)	0.37

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Role	Description
EC 5.99.1.2 (DNA topoisomerase) inhibitor	A topoisomerase inhibitor that inhibits the bacterial enzymes of the DNA topoisomerases, Type I class (EC 5.99.1.2) that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. These bacterial enzymes reduce the topological stress in the DNA structure by relaxing negatively, but not positively, supercoiled DNA.
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
organic heteropentacyclic compound
epsilon-lactone	Any lactone with a seven-membered ring.
organonitrogen heterocyclic compound	Any organonitrogen compound containing a cyclic component with nitrogen and at least one other element as ring member atoms.
tertiary alcohol	A tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (11)

Assay ID	Title	Year	Journal	Article
AID331827	Resistant index, ratio of IC50 for BCRP overexpressing mitoxantrone-resistant human HT29 cells to IC50 for human HT29 cells	2008	Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9	E-ring-modified 7-oxyiminomethyl camptothecins: Synthesis and preliminary in vitro and in vivo biological evaluation.
AID8663	Cytotoxicity against A549 tumor cell line determined by WST-1 assay	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins.
AID331826	Antiproliferative activity against BCRP overexpressing mitoxantrone-resistant human HT29 cells after 1 hr of drug exposure measured after 72 hrs	2008	Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9	E-ring-modified 7-oxyiminomethyl camptothecins: Synthesis and preliminary in vitro and in vivo biological evaluation.
AID745334	Cytotoxicity against human chemo-resistant T24 cells by WST assay	2013	European journal of medicinal chemistry, May, Volume: 63	Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents.
AID745335	Cytotoxicity against human A549 cells by WST assay	2013	European journal of medicinal chemistry, May, Volume: 63	Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents.
AID56882	Stimulation of pKMp27 DNA cleavage by human DNA topoisomerase I in presence of 0.1 uM of compound	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins.
AID208523	Cytotoxicity against T24 tumor cell line determined by WST-1 assay	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins.
AID84438	Cytotoxicity against HT-29 tumor cell line determined by WST-1 assay	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins.
AID331825	Antiproliferative activity against human HT29 cells after 1 hr of drug exposure measured after 72 hrs	2008	Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9	E-ring-modified 7-oxyiminomethyl camptothecins: Synthesis and preliminary in vitro and in vivo biological evaluation.
AID331823	Antiproliferative activity against human H460 cells after 1 hr of drug exposure measured after 72 hrs	2008	Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9	E-ring-modified 7-oxyiminomethyl camptothecins: Synthesis and preliminary in vitro and in vivo biological evaluation.
AID210938	Effect on Topo-I-mediated relaxation of supercoiled pUC19 plasmid DNA in calf thymus at 100 uM	1998	Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27	Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	4 (7.55)	18.2507
2000's	26 (49.06)	29.6817
2010's	20 (37.74)	24.3611
2020's	3 (5.66)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (1.89%)	5.53%
Reviews	6 (11.32%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	46 (86.79%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
pyridine azine : An organonitrogen compound of general structure RCH=N-N=CHR or RR'C=N-N=CRR'.	7.44	2	0	azaarene; mancude organic heteromonocyclic parent; monocyclic heteroarene; pyridines	environmental contaminant; NMR chemical shift reference compound
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	4.1	3	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.25	1	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	2.08	1	0	mitomycin	alkylating agent; antineoplastic agent
thymidine [no description available]	2	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
3-hydroxybutanal [no description available]	2.03	1	0
deoxycytidine [no description available]	2.02	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	9.28	53	1	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	7.01	1	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
etoposide [no description available]	4.08	3	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	4.89	6	0	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	2.02	1	0	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
irinotecan [no description available]	4.02	4	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
arginyl-glycyl-aspartic acid arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system	2.55	2	0	oligopeptide
sn 38 SN-38 : A member of the class of pyranoindolizinoquinolines that is (4S)-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione bearing two additional ethyl substituents at positions 4 and 11 as well as two additional hydroxy substituents at positions 4 and 9. It is the active metabolite of irinotecan and is ~1000 times more active than irinotecan itself.	3.56	2	0	delta-lactone; phenols; pyranoindolizinoquinoline; tertiary alcohol	antineoplastic agent; apoptosis inducer; drug metabolite; EC 5.99.1.2 (DNA topoisomerase) inhibitor
bn 80927 BN 80927: structure in first source	3.12	1	0
diflomotecan diflomotecan: a fluorinated E-ring modified camptothecin; structure in first source. diflomotecan : An organic heteropentacyclic compound that is (5R)-8-[(6,7-difluoroquinolin-3-yl)methyl]-5-ethyl-5-hydroxy-1,4,5,8-tetrahydrooxepino[3,4-c]pyridine-3,9-dione in which position 7 of the oxepinopyridine moiety is joined to position 3 of the difluoroquinoine ring by a single bond. An E-ring modified camptothecin analogue that has greater lactone stability in plasma compared with other topoisomerase I inhibitors.	4.05	4	0	epsilon-lactone; organic heteropentacyclic compound; organofluorine compound; organonitrogen heterocyclic compound; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
nsc 314622 NSC 314622: structure in first source	3.14	1	0
leupeptins Leupeptins: A group of acylated oligopeptides produced by Actinomycetes that function as protease inhibitors. They have been known to inhibit to varying degrees trypsin, plasmin, KALLIKREINS, papain and the cathepsins.	2.25	1	0
carboplatin [no description available]	2.02	1	0
betadex beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.	2.03	1	0	cyclodextrin
benzyloxycarbonylleucyl-leucyl-leucine aldehyde benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.	2.25	1	0	amino aldehyde; carbamate ester; tripeptide	proteasome inhibitor
st 1481 ST 1481: structure in first source	3.54	2	0
edotecarin [no description available]	3.14	1	0
pirarubicin [no description available]	2.02	1	0	anthracycline
glycolipids [no description available]	2.01	1	0
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	2.06	1	0
levoleucovorin Levoleucovorin: A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN.. (6S)-5-formyltetrahydrofolic acid : The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid.	3.8	2	1	5-formyltetrahydrofolic acid	antineoplastic agent; metabolite
deoxyguanosine [no description available]	2.02	1	0	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite

Condition	Relationship Strength	Studies	Trials
Hepatocellular Carcinoma [description not available]	2.58	2	0
Cancer of Liver [description not available]	2.77	3	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.58	2	0
Liver Neoplasms Tumors or cancer of the LIVER.	2.77	3	0
Lung Adenocarcinoma [description not available]	2.25	1	0
Adenocarcinoma, Basal Cell [description not available]	2.47	2	0
Cancer of Lung [description not available]	2.54	2	0
Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.	2.25	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.47	2	0
Lung Neoplasms Tumors or cancer of the LUNG.	2.54	2	0
Benign Neoplasms [description not available]	3.02	4	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.02	4	0
Cancer of Stomach [description not available]	3.82	2	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	3.82	2	1
Experimental Neoplasms [description not available]	2.45	2	0
Cancer of Colon [description not available]	2.93	4	0
Colonic Neoplasms Tumors or cancer of the COLON.	2.93	4	0
Carcinoma, Epidermoid [description not available]	2.42	2	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.41	2	0
Cancer of Mouth [description not available]	2.42	2	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.42	2	0
Mouth Neoplasms Tumors or cancer of the MOUTH.	2.42	2	0
Leucocythaemia [description not available]	2.93	1	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	2.93	1	0
Lymph Node Metastasis [description not available]	2.02	1	0
Cancer of Pancreas [description not available]	2.02	1	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.02	1	0
Astrocytoma, Grade IV [description not available]	2.04	1	0
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	7.04	1	0
Leukemia L 1210 [description not available]	2	1	0
Experimental Leukemia [description not available]	2	1	0
Osteogenic Sarcoma [description not available]	2	1	0
Choriocarcinoma A malignant metastatic form of trophoblastic tumors. Unlike the HYDATIDIFORM MOLE, choriocarcinoma contains no CHORIONIC VILLI but rather sheets of undifferentiated cytotrophoblasts and syncytiotrophoblasts (TROPHOBLASTS). It is characterized by the large amounts of CHORIONIC GONADOTROPIN produced. Tissue origins can be determined by DNA analyses: placental (fetal) origin or non-placental origin (CHORIOCARCINOMA, NON-GESTATIONAL).	2	1	0
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	2	1	0
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	2.4	2	0
Cancer of Prostate [description not available]	2	1	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2	1	0
Breast Cancer [description not available]	7.01	1	0
Carcinoma, Anaplastic [description not available]	2.01	1	0
Granulocytic Leukemia [description not available]	2.01	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	2.01	1	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	2.01	1	0
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	2.01	1	0

homocamptothecin

Description

Cross-References

Synonyms (19)

Research Excerpts

Overview

Pharmacokinetics

Bioavailability

Roles (2)

Drug Classes (4)

Bioassays (11)

Research

Studies (53)

Market Indicators

Research Demand Index: 10.69

Study Types

homocamptothecin

Description

Cross-References

Synonyms (19)

Research Excerpts

Overview

Pharmacokinetics

Bioavailability

Roles (2)

Drug Classes (4)

Bioassays (11)

Research

Studies (53)

Market Indicators

Research Demand Index: 10.69

Study Types

Related Drugs (29)

Related Conditions (43)